EIP
SPRY icon

Epoch Investment Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Epoch Investment Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-89,980
Closed -$904K – 281
2025
Q3 		$904K Buy
89,980
+17,200
+24% +$247K 0.01% 243
2025
Q2 		$1.27M Sell
72,780
-46,202
-39% -$667K 0.01% 236
2025
Q1 		$1.5M Buy
+118,982
New +$1.43M 0.01% 231

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Epoch Investment Partners's SPRY Position: Q4 2025 in Review

Epoch Investment Partners sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 89,980 shares — an estimated $904K sold.

Epoch Investment Partners first reported a position in SPRY in Q1 2025 and held it in 3 quarters. The position peaked at $1.5M in Q1 2025. 190 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Epoch Investment Partners reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Epoch Investment Partners sold 89,980 ARS Pharmaceuticals shares in Q4 2025, an estimated $904K.
  • Epoch Investment Partners first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Epoch Investment Partners's ARS Pharmaceuticals position peaked at $1.5M in Q1 2025.
  • 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Epoch Investment Partners's 13F filing for Q4 2025, filed 13 Feb 2026.